Developer docs
API playgroundTry for free, no card

Search company profiles

VIVAN Therapeutics

Full company profile

uuid0002i2e

Namestring
VIVAN Therapeutics
Legal namestring
My Personal Therapeutics Ltd.
Websiteurl
vivantx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

VIVAN Therapeutics (legally My Personal Therapeutics Ltd.) is a London-based precision oncology company that delivers personalized cancer treatment recommendations using an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML-based drug matching. The company operates two core products under a unified workflow: TuMatch, a clinical decision-support software interface, and the Personal Discovery Process (PDP), a comprehensive genomics-based drug screening technology. Under PDP, a patient's entire tumor exome is sequenced, the resulting tumor network (up to 20 cancer-associated mutations) is engineered into up to 500,000 fruit fly avatars, and up to 2,000 FDA/NICE-approved drugs, including non-cancer drugs, are screened to identify effective combination therapy cocktails. Treatment recommendations are delivered as a ranked report within 2-5 days of screening data upload, with the full PDP taking 4-5 months from tumor and blood sequencing. A concierge Second Opinion service extends the offering for patients seeking additional expert review.

VIVAN's primary customer segments are patients with gastrointestinal (colorectal, pancreatic) and lung cancers, patients with rare cancers or tumors of unknown origin, and patients with pre-malignant gut lesions for whom standard protocols have failed or do not exist. The go-to-market model is sales-led and physician-mediated: patients initiate the process via the company's website (Calendly consultation booking) and treatment recommendations are reviewed by the patient's oncologist and tumour board before clinical application. Earned media coverage in New Scientist, Forbes, Wired, and Business Insider, combined with physician referrals, drives demand generation. Pricing is quote-based and not publicly disclosed, structured as multi-year contracts per patient engagement.

The underlying PDP technology was developed at the Icahn School of Medicine at Mount Sinai and is licensed exclusively to My Personal Therapeutics Ltd. VIVAN has secured strategic partnerships with Mt. Sinai and, as of November 2025, with the UK Medical Research Council (MRC) Laboratory of Medical Sciences to extend the platform into metabolic-oncology research on KRAS mutations, diabetes, and diet. The company has raised approximately $5.3M across disclosed rounds (SFC Capital 2019, Reflect Ventures and VOYAGERS Health-Tech Fund 2021, European Innovation Council 2022) plus additional investment from the Longevity Investor Network in 2024 and 2025.

Short descriptiontext

VIVAN Therapeutics is a London-based precision oncology company that uses an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML drug matching to deliver personalized cancer treatment recommendations to patients with gastrointestinal, lung, rare, and treatment-resistant cancers, via physician-mediated referrals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology services, personalized cancer treatment, drug screening platform, clinical decision support, genomics-based therapeutics
Industry3 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Precision Oncology Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Personalized Cancer Treatment Recommendations (TuMatch/PDP)
TypeProfessional Services
Description

VIVAN Therapeutics generates revenue by providing personalized drug screening and treatment recommendation reports to patients and their oncologists. The Personal Discovery Process (PDP) takes 4–5 months after tumor and blood sequencing results are available. Treatment recommendations are delivered as reports ranked by efficiency, reviewed by the patient's oncologist and tumour board before clinical application. The company operates as My Personal Therapeutics Ltd. (trading as Vivan Therapeutics).

vivantx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Personalized drug screening and treatment recommendation (TuMatch)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based and not publicly disclosed. The process involves tumor and blood sequencing followed by up to 2,000 drug screenings and delivery of a ranked treatment recommendations report within 2–5 days of screening data upload.

vivantx.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1TuMatch
Description

Rapid, personalized clinical decision support software that analyzes tumor genetic profiles to identify optimal drug combinations.

vivantx.com
+1 more record
Core offering1 text field

VIVAN Therapeutics delivers personalized cancer treatment recommendations by sequencing a patient's tumor exome, engineering the identified mutations into fruit fly (Drosophila) avatars, and using robotics and AI/ML to screen up to 2,000 FDA/NICE-approved drugs (including non-cancer drugs) across up to 500,000 avatars. The output is a ranked treatment recommendation report delivered to the patient and their oncologist/tumour board for clinical review.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 500,000 fruit fly avatars engineered per patient to screen drug combinations
+4 more records
Product overview1 text field

VIVAN Therapeutics offers a unified precision oncology platform centered on TuMatch and the Personal Discovery Process (PDP). TuMatch serves as the clinical decision support software interface, while PDP is the underlying genomic-based drug screening technology that engineers patient-specific tumor mutations into fruit fly avatars for high-throughput drug testing. The platform evaluates up to 2,000 FDA/NICE approved drugs (including non-cancer drugs) using 500,000 fruit fly avatars to identify personalized drug combinations. Concierge services including Second Opinion complement the core offerings for patients seeking additional consultation.

Product and service3 records
1TuMatch
CategoryClinical Decision Support Software
Description

Rapid, personalized clinical decision support software that analyzes the genetic and molecular profile of a patient's tumor to identify the most effective therapies and drug combinations for individual cancer patients.

2Personal Discovery Process (PDP)
CategoryPersonalized Drug Screening Service
Description

Comprehensive genomics-based drug screening service that engineers a patient's tumor mutations into fruit fly avatars and screens up to 2,000 FDA/NICE-approved drugs to identify personalized drug cocktails targeting the patient's specific tumor network.

3Second Opinion
CategoryConcierge Oncology Consultation
Description

Concierge service providing second opinion consultation for patients seeking additional expert review of their cancer treatment options.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

VIVAN Therapeutics and the MRC Laboratory of Medical Sciences announced a partnership to study how KRAS mutations, diabetes, and diet influence chemotherapy responses, utilizing VIVAN's in vivo fruit fly screening platform. The collaboration aims to develop personalized cancer treatment recommendations for patients with Type 2 diabetes or obesity. The initiative is supported by the UK's MRC to advance translational research in personalized oncology.

Strategic tierCoreTypeTechnology or Integration
Description

VIVAN's Personal Discovery Process was developed in partnership with Mt. Sinai Medical Center / Icahn School of Medicine in New York. The technology underlying PDP was developed by scientists at the Icahn School of Medicine and is backed by decades of academic cancer research. PDP methods are licensed exclusively to My Personal Therapeutics (trading as VIVAN Therapeutics).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Notable Labs
TypeDirect peer
Description

Notable Labs uses patient-specific functional drug screening (via cell-based models) combined with AI to identify personalized cancer treatments. Direct peer because both companies employ patient-derived biological models + AI to recommend personalized combination therapies for refractory cancers.

TypeDirect peer
Description

xCures is an AI-driven precision oncology platform that aggregates patient records and molecular data to identify personalized treatment options for advanced cancer patients. Direct peer because it similarly uses AI/ML to match hard-to-treat cancer patients with non-standard, often off-label drug combinations.

TypeDirect peer
Description

Strata provides molecular-guided precision oncology treatment selection for advanced cancer patients, combining tumor profiling with treatment recommendation software. Direct peer as both deliver clinical decision support for oncologists seeking personalized therapy choices.

4Tempus AI
TypeBroad incumbent
Description

Tempus is a leading AI-powered precision medicine company combining multi-modal data (genomics, imaging, clinical) to support oncologist treatment decisions at scale. Broad incumbent offering overlapping clinical decision support but with vastly larger datasets, established reimbursement, and broader cancer-type coverage.

TypeBroad incumbent
Description

Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling of tumors and associated clinical decision support tools used widely by oncologists. Broad incumbent offering molecular-guided treatment selection with established FDA-cleared tests and payer coverage.

TypeBroad incumbent
Description

Caris offers molecular profiling (MI Profile) and AI-driven precision oncology decision support with multiple service lines across diagnostics and treatment selection. Broad incumbent providing molecular-guided therapy recommendations comparable to VIVAN's TuMatch service.

TypeEmerging player
Description

Lantern Pharma uses AI and machine learning to develop and identify oncology drug combinations, particularly focused on drug repurposing for rare and refractory cancers. Emerging player with overlapping AI-oncology approach but focused on drug development rather than patient-specific screening.

TypeBroad incumbent
Description

Personalis provides tumor genomic profiling and immune-based biomarker analysis for cancer treatment selection. Broad incumbent operating in adjacent precision oncology space with overlap in multi-gene tumor characterization for therapy decisions.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy and precision oncology company providing blood-based tumor profiling for treatment selection. Broad incumbent offering genomic-guided clinical decision support with FDA-approved tests and established commercial scale.

TypeEmerging player
Description

Massive Bio uses AI to match cancer patients to clinical trials and personalized treatment options, including off-label and combination therapies. Emerging player with overlapping AI-driven personalized oncology matching mission for hard-to-treat cancer patients.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VIVAN Therapeutics

Precision Oncology Servicesvivantx.com

VIVAN Therapeutics is a London-based precision oncology company that uses an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML drug matching to deliver personalized cancer treatment recommendations to patients with gastrointestinal, lung, rare, and treatment-resistant cancers, via physician-mediated referrals.

What VIVAN Therapeutics does

VIVAN Therapeutics (legally My Personal Therapeutics Ltd.) is a London-based precision oncology company that delivers personalized cancer treatment recommendations using an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML-based drug matching. The company operates two core products under a unified workflow: TuMatch, a clinical decision-support software interface, and the Personal Discovery Process (PDP), a comprehensive genomics-based drug screening technology. Under PDP, a patient's entire tumor exome is sequenced, the resulting tumor network (up to 20 cancer-associated mutations) is engineered into up to 500,000 fruit fly avatars, and up to 2,000 FDA/NICE-approved drugs, including non-cancer drugs, are screened to identify effective combination therapy cocktails. Treatment recommendations are delivered as a ranked report within 2-5 days of screening data upload, with the full PDP taking 4-5 months from tumor and blood sequencing. A concierge Second Opinion service extends the offering for patients seeking additional expert review.

VIVAN's primary customer segments are patients with gastrointestinal (colorectal, pancreatic) and lung cancers, patients with rare cancers or tumors of unknown origin, and patients with pre-malignant gut lesions for whom standard protocols have failed or do not exist. The go-to-market model is sales-led and physician-mediated: patients initiate the process via the company's website (Calendly consultation booking) and treatment recommendations are reviewed by the patient's oncologist and tumour board before clinical application. Earned media coverage in New Scientist, Forbes, Wired, and Business Insider, combined with physician referrals, drives demand generation. Pricing is quote-based and not publicly disclosed, structured as multi-year contracts per patient engagement.

The underlying PDP technology was developed at the Icahn School of Medicine at Mount Sinai and is licensed exclusively to My Personal Therapeutics Ltd. VIVAN has secured strategic partnerships with Mt. Sinai and, as of November 2025, with the UK Medical Research Council (MRC) Laboratory of Medical Sciences to extend the platform into metabolic-oncology research on KRAS mutations, diabetes, and diet. The company has raised approximately $5.3M across disclosed rounds (SFC Capital 2019, Reflect Ventures and VOYAGERS Health-Tech Fund 2021, European Innovation Council 2022) plus additional investment from the Longevity Investor Network in 2024 and 2025.

VIVAN Therapeutics firmographics

Firmographics
Name
VIVAN Therapeutics
Legal name
My Personal Therapeutics Ltd.
Website
https://vivantx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
VIVAN Therapeutics is a London-based precision oncology company that uses an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML drug matching to deliver personalized cancer treatment recommendations to patients with gastrointestinal, lung, rare, and treatment-resistant cancers, via physician-mediated referrals.
Ownership category
akta.pro rank

VIVAN Therapeutics industry classification

Industry
Product category
Precision Oncology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology services
  • Personalized cancer treatment
  • Drug screening platform
  • Clinical decision support
  • Genomics-based therapeutics

Where VIVAN Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

VIVAN Therapeutics business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Personalized Cancer Treatment Recommendations (TuMatch/PDP): VIVAN Therapeutics generates revenue by providing personalized drug screening and treatment recommendation reports to patients and their oncologists. The Personal Discovery Process (PDP) takes 4–5 months after tumor and blood sequencing results are available. Treatment recommendations are delivered as reports ranked by efficiency, reviewed by the patient's oncologist and tumour board before clinical application. The company operates as My Personal Therapeutics Ltd. (trading as Vivan Therapeutics).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPersonalized drug screening and treatment recommendation (TuMatch)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

VIVAN Therapeutics product offering

Product offering

Core offering

VIVAN Therapeutics delivers personalized cancer treatment recommendations by sequencing a patient's tumor exome, engineering the identified mutations into fruit fly (Drosophila) avatars, and using robotics and AI/ML to screen up to 2,000 FDA/NICE-approved drugs (including non-cancer drugs) across up to 500,000 avatars. The output is a ranked treatment recommendation report delivered to the patient and their oncologist/tumour board for clinical review.

Product overview

VIVAN Therapeutics offers a unified precision oncology platform centered on TuMatch and the Personal Discovery Process (PDP). TuMatch serves as the clinical decision support software interface, while PDP is the underlying genomic-based drug screening technology that engineers patient-specific tumor mutations into fruit fly avatars for high-throughput drug testing. The platform evaluates up to 2,000 FDA/NICE approved drugs (including non-cancer drugs) using 500,000 fruit fly avatars to identify personalized drug combinations. Concierge services including Second Opinion complement the core offerings for patients seeking additional consultation.

Differentiator

Problem solved

Functional benefit

Brands

  • TuMatch: Rapid, personalized clinical decision support software that analyzes tumor genetic profiles to identify optimal drug combinations.
  • Personal Discovery Process (PDP)

Products and services

  • TuMatch Rapid, personalized clinical decision support software that analyzes the genetic and molecular profile of a patient's tumor to identify the most effective therapies and drug combinations for individual cancer patients.
  • Personal Discovery Process (PDP) Comprehensive genomics-based drug screening service that engineers a patient's tumor mutations into fruit fly avatars and screens up to 2,000 FDA/NICE-approved drugs to identify personalized drug cocktails targeting the patient's specific tumor network.
  • Second Opinion Concierge service providing second opinion consultation for patients seeking additional expert review of their cancer treatment options.

Quantifiable outcome

  • Up to 500,000 fruit fly avatars engineered per patient to screen drug combinations
  • +4 more outcomes

Companies that use VIVAN Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

VIVAN Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

VIVAN Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MRC Laboratory of Medical SciencescoreStrategic or Co-development Partner · 26 November 2025VIVAN Therapeutics and the MRC Laboratory of Medical Sciences announced a partnership to study how KRAS mutations, diabetes, and diet influence chemotherapy responses, utilizing VIVAN's in vivo fruit fly screening platform. The collaboration aims to develop personalized cancer treatment recommendations for patients with Type 2 diabetes or obesity. The initiative is supported by the UK's MRC to advance translational research in personalized oncology.
  • Mt. Sinai Medical Center (Icahn School of Medicine)coreTechnology or IntegrationVIVAN's Personal Discovery Process was developed in partnership with Mt. Sinai Medical Center / Icahn School of Medicine in New York. The technology underlying PDP was developed by scientists at the Icahn School of Medicine and is backed by decades of academic cancer research. PDP methods are licensed exclusively to My Personal Therapeutics (trading as VIVAN Therapeutics).

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

VIVAN Therapeutics competitors and assessment

Company assessment

Direct peers

  • Notable Labs: Notable Labs uses patient-specific functional drug screening (via cell-based models) combined with AI to identify personalized cancer treatments. Direct peer because both companies employ patient-derived biological models + AI to recommend personalized combination therapies for refractory cancers.
  • xCures: xCures is an AI-driven precision oncology platform that aggregates patient records and molecular data to identify personalized treatment options for advanced cancer patients. Direct peer because it similarly uses AI/ML to match hard-to-treat cancer patients with non-standard, often off-label drug combinations.
  • Strata Oncology: Strata provides molecular-guided precision oncology treatment selection for advanced cancer patients, combining tumor profiling with treatment recommendation software. Direct peer as both deliver clinical decision support for oncologists seeking personalized therapy choices.

Broad incumbents

  • Tempus AI: Tempus is a leading AI-powered precision medicine company combining multi-modal data (genomics, imaging, clinical) to support oncologist treatment decisions at scale. Broad incumbent offering overlapping clinical decision support but with vastly larger datasets, established reimbursement, and broader cancer-type coverage.
  • Foundation Medicine: Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling of tumors and associated clinical decision support tools used widely by oncologists. Broad incumbent offering molecular-guided treatment selection with established FDA-cleared tests and payer coverage.
  • Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven precision oncology decision support with multiple service lines across diagnostics and treatment selection. Broad incumbent providing molecular-guided therapy recommendations comparable to VIVAN's TuMatch service.
  • Personalis: Personalis provides tumor genomic profiling and immune-based biomarker analysis for cancer treatment selection. Broad incumbent operating in adjacent precision oncology space with overlap in multi-gene tumor characterization for therapy decisions.
  • Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company providing blood-based tumor profiling for treatment selection. Broad incumbent offering genomic-guided clinical decision support with FDA-approved tests and established commercial scale.

Emerging players

  • Lantern Pharma: Lantern Pharma uses AI and machine learning to develop and identify oncology drug combinations, particularly focused on drug repurposing for rare and refractory cancers. Emerging player with overlapping AI-oncology approach but focused on drug development rather than patient-specific screening.
  • Massive Bio: Massive Bio uses AI to match cancer patients to clinical trials and personalized treatment options, including off-label and combination therapies. Emerging player with overlapping AI-driven personalized oncology matching mission for hard-to-treat cancer patients.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

VIVAN Therapeutics social profiles

Digital presence

VIVAN Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VIVAN Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

VIVAN Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VIVAN Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VIVAN Therapeutics

What does VIVAN Therapeutics do?

VIVAN Therapeutics delivers personalized cancer treatment recommendations by sequencing a patient's tumor exome, engineering the identified mutations into fruit fly (Drosophila) avatars, and using robotics and AI/ML to screen up to 2,000 FDA/NICE-approved drugs (including non-cancer drugs) across up to 500,000 avatars. The output is a ranked treatment recommendation report delivered to the patient and their oncologist/tumour board for clinical review.

Is VIVAN Therapeutics a public or private company?

VIVAN Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was VIVAN Therapeutics founded?

VIVAN Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is VIVAN Therapeutics based?

VIVAN Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does VIVAN Therapeutics make money?

One revenue line is on record: personalized Cancer Treatment Recommendations (TuMatch/PDP).

Who are VIVAN Therapeutics's main competitors?

Direct peers on record are Notable Labs, xCures and Strata Oncology. Broad incumbents are Tempus AI, Foundation Medicine, Caris Life Sciences, Personalis and Guardant Health. Emerging players are Lantern Pharma and Massive Bio.

Does VIVAN Therapeutics have an API?

No public API is recorded for VIVAN Therapeutics.

What industry is VIVAN Therapeutics in?

VIVAN Therapeutics's product category is Precision Oncology Services. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coVivan clears UAE approval to launch AI cancer-matching study in Abu Dhabi | Dealroom NewsVivan Therapeutics received UAE regulatory approval to launch a clinical registration study of its AI software TuMatch at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the tool in colorectal cancer patients, enrolling at least 10 people, led by Prof. Humaid Al Shamsi. The study aims to capture health economics data to support reimbursement talks.Business & FinancialHub71 Startup, Vivan Therapeutics Set To Begin Tumatchtm Clinical Registration Study At Burjeel Cancer Institute, Abu DhabiVivan Therapeutics received regulatory approvals to begin its TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. The prospective study will enroll at least 10 colorectal cancer patients and generate health-economics evidence for reimbursement. Data will support CE mark and FDA submissions for the AI-enabled decision-support tool.Business & FinancialVivan Therapeutics Set To Begin Tumatchtm Clinical Registration Study At Burjeel Cancer Institute, Abu DhabiVivan Therapeutics received regulatory approvals to begin its TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the AI-enabled decision support tool in colorectal cancer patients, enrolling at least 10, and will generate health economics data for reimbursement discussions.EIN PresswireVivan Therapeutics set to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu DhabiVivan Therapeutics received regulatory approvals to begin its TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the AI-enabled decision support software in colorectal cancer patients, enrolling at least 10, and will generate health economics data for reimbursement discussions.EIN PresswireVivan Therapeutics set to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu DhabiVivan Therapeutics received regulatory approvals to begin its TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the AI-enabled decision support software in colorectal cancer patients, enrolling at least 10, and will generate health economics data for reimbursement discussions.EIN PresswireHub71 Startup, Vivan Therapeutics to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu DhabiVivan Therapeutics received regulatory approvals to begin its TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the AI-enabled decision support tool in colorectal cancer patients, enrolling at least 10, and will generate health economics data for reimbursement discussions.The Pharma LetterVivan and Ad Atomica pair tumor genotype data with AI drug designVivan Therapeutics and Ad Atomica announced a discovery collaboration combining Vivan's genotype-resolved cancer screening data with Ad Atomica's AI-driven small molecule design platform. The partnership aims to use the combined data for drug discovery.OncoDailyLaura Towart: Vivan Therapeutics Featured in Green Street News for Cancer InnovationVivan Therapeutics, a London-based cancer treatment company, was featured in Green Street News' 'Weird & Wonderful' section highlighting innovative UK life sciences companies. The company uses fruit fly genetics combined with artificial intelligence to deliver personalized cancer therapy recommendations, initially focused on gastrointestinal cancers, and is based at White City Place in London.EIN PresswireVivan Therapeutics and the MRC Laboratory of Medical Sciences Announce a Pioneering PartnershipVivan Therapeutics and the MRC Laboratory of Medical Sciences have announced a pioneering research partnership to investigate how KRAS mutations, diabetes, and diet influence chemotherapy responses in cancer patients. Vivan Therapeutics will contribute its automated in vivo screening platform, which uses genetically modified fruit flies carrying human cancer mutations to rapidly test hundreds of thousands of drug combinations. The collaboration aims to develop personalized cancer treatment recommendations specifically for patients with Type 2 diabetes or obesity, supported by the MRC's Business Engagement Fund.